Pasithea Therapeutics (NASDAQ:KTTA) Trading Down 0.4%

Pasithea Therapeutics Corp. (NASDAQ:KTTA)’s stock price traded down 0.4% during trading on Thursday . The company traded as low as $7.12 and last traded at $7.12. Approximately 702 shares traded hands during trading, a decline of 93% from the average daily volume of 9,970 shares. The stock had previously closed at $7.15.

Pasithea Therapeutics Price Performance

The firm’s 50-day simple moving average is $7.35 and its two-hundred day simple moving average is $7.29.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pasithea Therapeutics stock. Vanguard Group Inc. increased its stake in shares of Pasithea Therapeutics Corp. (NASDAQ:KTTA) by 345.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,583 shares of the company’s stock after purchasing an additional 43,883 shares during the period. Vanguard Group Inc. owned approximately 0.25% of Pasithea Therapeutics worth $74,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 23.92% of the company’s stock.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers.